NZ573132A - Administration of anti-cd3 antibodies in the treatment of autoimmune diseases - Google Patents
Administration of anti-cd3 antibodies in the treatment of autoimmune diseasesInfo
- Publication number
- NZ573132A NZ573132A NZ573132A NZ57313207A NZ573132A NZ 573132 A NZ573132 A NZ 573132A NZ 573132 A NZ573132 A NZ 573132A NZ 57313207 A NZ57313207 A NZ 57313207A NZ 573132 A NZ573132 A NZ 573132A
- Authority
- NZ
- New Zealand
- Prior art keywords
- trx4
- day
- antibody
- administered
- amount
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 82
- 208000023275 Autoimmune disease Diseases 0.000 title description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 73
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 73
- 238000001990 intravenous administration Methods 0.000 claims abstract description 40
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 30
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 101100208110 Arabidopsis thaliana TRX4 gene Proteins 0.000 description 300
- 101100425276 Dictyostelium discoideum trxD gene Proteins 0.000 description 300
- 101100154863 Mus musculus Txndc2 gene Proteins 0.000 description 300
- 210000001744 T-lymphocyte Anatomy 0.000 description 130
- 108091008874 T cell receptors Proteins 0.000 description 102
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 101
- 238000001802 infusion Methods 0.000 description 70
- 210000004698 lymphocyte Anatomy 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 36
- 230000007423 decrease Effects 0.000 description 28
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 20
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 19
- 230000003285 pharmacodynamic effect Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 231100000673 dose–response relationship Toxicity 0.000 description 17
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 16
- 210000003719 b-lymphocyte Anatomy 0.000 description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
- 230000001052 transient effect Effects 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 206010025327 Lymphopenia Diseases 0.000 description 7
- 210000000207 lymphocyte subset Anatomy 0.000 description 7
- 231100001023 lymphopenia Toxicity 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 238000012286 ELISA Assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000008024 pharmaceutical diluent Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010025280 Lymphocytosis Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108010056243 alanylalanine Proteins 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000263 nonmitogenic effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ599379A NZ599379A (en) | 2006-06-06 | 2007-06-05 | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44762806A | 2006-06-06 | 2006-06-06 | |
| US92148506P | 2006-06-06 | 2006-06-06 | |
| PCT/US2007/013232 WO2007145941A2 (en) | 2006-06-06 | 2007-06-05 | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ573132A true NZ573132A (en) | 2012-05-25 |
Family
ID=38832328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ573132A NZ573132A (en) | 2006-06-06 | 2007-06-05 | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090258001A1 (OSRAM) |
| EP (2) | EP2023955A4 (OSRAM) |
| JP (1) | JP2009539841A (OSRAM) |
| AU (1) | AU2007258694B2 (OSRAM) |
| CA (1) | CA2653387A1 (OSRAM) |
| NZ (1) | NZ573132A (OSRAM) |
| WO (1) | WO2007145941A2 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1753783B1 (en) | 2004-06-03 | 2014-08-06 | Novimmune SA | Anti-cd3 antibodies and methods of use thereof |
| SG177944A1 (en) | 2005-07-11 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| AU2007260687B2 (en) | 2006-06-14 | 2013-12-12 | Provention Bio, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| AU2009303318B2 (en) * | 2008-10-10 | 2016-06-30 | Aptevo Research And Development Llc | TCR complex immunotherapeutics |
| US8609364B2 (en) * | 2009-05-07 | 2013-12-17 | bioM{tilde over (e)}rieux, Inc. | Methods for antimicrobial resistance determination |
| US20120269826A1 (en) * | 2009-10-20 | 2012-10-25 | Mckee Charlotte | Anti-cd3 antibody dosing in autoimmune disease |
| JP2013508391A (ja) * | 2009-10-20 | 2013-03-07 | グラクソ グループ リミテッド | 体重増加を予防するために抗ｃｄ３抗体を使用する方法 |
| JP6184695B2 (ja) | 2009-12-04 | 2017-08-23 | ジェネンテック， インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
| MX349057B (es) | 2010-11-30 | 2017-07-07 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad. |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| MX359775B (es) | 2011-10-31 | 2018-10-10 | Chugai Pharmaceutical Co Ltd | Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada. |
| RU2673153C2 (ru) | 2012-04-20 | 2018-11-22 | АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи | Полипептиды, связывающиеся с cd3 |
| CN104684585A (zh) * | 2012-08-03 | 2015-06-03 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗溶酶体贮积症的环糊精 |
| CA2943943C (en) | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| JP6894702B2 (ja) | 2014-05-13 | 2021-06-30 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| MX2018007781A (es) | 2015-12-28 | 2018-09-05 | Chugai Pharmaceutical Co Ltd | Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc). |
| WO2017159287A1 (ja) | 2016-03-14 | 2017-09-21 | 中外製薬株式会社 | 癌の治療に用いるための細胞傷害誘導治療剤 |
| US20230181557A1 (en) * | 2017-06-28 | 2023-06-15 | Mitocholine Ltd | Compositions for synergistically enhancing mitochondrial function |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| TW202039578A (zh) * | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2020247929A1 (en) * | 2019-06-07 | 2020-12-10 | Adimab, Llc | High affinity anti-cd3 antibodies, and methods for their generation and use |
| WO2020250940A1 (ja) * | 2019-06-11 | 2020-12-17 | 小野薬品工業株式会社 | 免疫抑制剤 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| KR20240160120A (ko) | 2022-02-18 | 2024-11-08 | 베렌 테라퓨틱스 피.비.씨. | 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법 |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658019A (en) | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
| EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US6406696B1 (en) * | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| EP0497883B1 (en) * | 1989-10-27 | 1998-07-15 | Arch Development Corporation | Compositions and their use for promoting immunopotentiation |
| US6750325B1 (en) * | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JP3111024B2 (ja) * | 1995-07-19 | 2000-11-20 | キヤノン株式会社 | カラーフィルタの製造装置及び製造方法及び表示装置の製造方法及び表示装置を備えた装置の製造方法 |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US7041289B1 (en) | 1997-12-05 | 2006-05-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for treating established spontaneous auto-immune diseases in mammals |
| CA2224256C (en) | 1997-12-09 | 2013-04-30 | I.N.S.E.R.M. | Method for treating established spontaneous auto-immune diseases in mammals |
| GB9815909D0 (en) * | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE490518T1 (de) * | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2508264A1 (en) * | 2002-12-05 | 2004-06-24 | Protein Design Labs, Inc. | Methods of treatment of ulcerative colitis with anti-cd3 antibodies |
| DE10336334B3 (de) * | 2003-08-08 | 2005-08-04 | Cnh Baumaschinen Gmbh | Hydraulisches Steuersystem für Baumaschinenen, insbesondere für Bagger |
| WO2005048935A2 (en) * | 2003-11-14 | 2005-06-02 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| AU2005213449A1 (en) * | 2004-02-04 | 2005-08-25 | The La Jolla Institute For Allergy And Immunology | Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity |
| EP1753783B1 (en) * | 2004-06-03 | 2014-08-06 | Novimmune SA | Anti-cd3 antibodies and methods of use thereof |
| SG177944A1 (en) * | 2005-07-11 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
-
2007
- 2007-06-05 JP JP2009514336A patent/JP2009539841A/ja active Pending
- 2007-06-05 US US11/810,235 patent/US20090258001A1/en not_active Abandoned
- 2007-06-05 AU AU2007258694A patent/AU2007258694B2/en not_active Ceased
- 2007-06-05 WO PCT/US2007/013232 patent/WO2007145941A2/en not_active Ceased
- 2007-06-05 CA CA002653387A patent/CA2653387A1/en not_active Abandoned
- 2007-06-05 NZ NZ573132A patent/NZ573132A/en not_active IP Right Cessation
- 2007-06-05 EP EP07795754A patent/EP2023955A4/en not_active Withdrawn
- 2007-06-05 EP EP11190677A patent/EP2433650A3/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007258694B2 (en) | 2011-12-22 |
| EP2433650A3 (en) | 2012-12-19 |
| EP2023955A4 (en) | 2009-10-28 |
| CA2653387A1 (en) | 2007-12-21 |
| US20090258001A1 (en) | 2009-10-15 |
| AU2007258694A1 (en) | 2007-12-21 |
| WO2007145941A2 (en) | 2007-12-21 |
| WO2007145941A3 (en) | 2008-09-25 |
| EP2023955A2 (en) | 2009-02-18 |
| EP2433650A2 (en) | 2012-03-28 |
| JP2009539841A (ja) | 2009-11-19 |
| WO2007145941A8 (en) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007258694B2 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
| AU2016200435B2 (en) | Anti-ox40 antibodies and methods of using the same | |
| WO2012027328A2 (en) | Anti-ox40 antibodies and methods of using the same | |
| US20200181274A1 (en) | Bispecific antibodies that bind cd 123 cd3 | |
| EP3390450A1 (en) | Anti-cd28 humanized antibodies formulated for administration to humans | |
| KR20200128415A (ko) | 중증 천식 치료를 위한 항 cd6 항체 | |
| CN112312971A (zh) | 结合cd123和cd3的双特异性抗体的给药 | |
| AU2020251987A1 (en) | Methods of reducing large granular lymphocyte and natural killer cell levels | |
| KR20210016426A (ko) | Cd123 및 cd3에 결합하는 이중특이적 항체의 투약 | |
| AU2021352981A1 (en) | Anti-cd94 antibodies and methods of use thereof | |
| AU2012201443B2 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
| JP2022502380A (ja) | 抗ｃｄ１５４抗体の安全な投与を提供する方法 | |
| KR20210016332A (ko) | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 | |
| CN110546167A (zh) | 以抗-cd52抗体治疗多发性硬化症 | |
| WO2025231445A1 (en) | Methods of using lfa3-fc fusion proteins | |
| TW202146452A (zh) | 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥 | |
| KR20210016333A (ko) | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: GLAXO GROUP LIMITED, GB Free format text: OLD OWNER(S): TOLERX, INC. |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 JUN 2017 BY THOMSON REUTERS Effective date: 20140320 |
|
| LAPS | Patent lapsed |